All In Biotech

Drug Trial Radar · NCT03352726

A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects

An Open-label Phase I Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects

Last checked: Nov 19, 2026Latest source record: Jul 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Nov 24, 2017

Primary completion

Jun 29, 2018

Study completion Jun 29, 2018

Sponsor

Lead sponsor
DBV TechnologiesIndustry
Sponsor type
Industry
First posted
Nov 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to assess the biological potency of the In-House Reference Preparation (IHRP) of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic subjects.

Conditions

  • Peanut Allergy

Interventions

  • DBV712 IHRPDrug

    DBV712 Solution for Skin Prick Test

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Biological potency of the In-House Reference peanut proteins extract (DBV712-IHRP) in arbitrary Biological Units (BU)Time frame: 1 day to 2 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Children's Hospital Colorado

    Aurora, Colorado

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.